Australian company AdAlta (ASX:1AD) has announced the appointment of two new directors, including experienced industry executives Michelle Burke and Iain Ross.
The clinical-stage company is using its proprietary i-body technology platform to solve challenging drug-targeting problems and generate a promising new class of single-domain antibody-enabled protein and cell therapeutics.
Ms Burke has served as the industry-nominated PBAC member since 2017. She is currently a non-executive director of Cell Therapies and the Olivia Newton-John Cancer Research Institute. Ms Burke previously served on the board of AusBiotech, including as its chair. Her industry roles included senior positions at Bristol Myers Squibb and GSK.
AdAlta also announced the appointment of Iain Ross to its board.
Mr Ross has more than four decades of experience in the international life sciences and technology industries. He has previously held significant roles in a wide array of multinational companies such as Sandoz, Hoffman La Roche, Reed Business Publishing, and Celltech.
AdAlta chair Dr Paul MacLeman said, “Michelle is a highly experienced healthcare executive with in-depth knowledge of both business practices and scientific methodology in the biotechnology sector. We look forward to leveraging her proficiency in cell therapies, strategy, and governance as AdAlta continues to advance its development strategy. Iain’s decades of experience in the international biotechnology space including in global capital markets and financing will also be invaluable to AdAlta as it continues to grow. His track record in successfully positioning businesses for growth aligns with our vision of developing and commercialising the next generation of protein therapeutics.”
